Vazyme(SH:688105) Zheng Quan Zhi Xing·2025-09-02 12:12Group 1 - The major shareholder, Guoshou Chengda, plans to reduce its stake in Nanjing Novogene Bioinformatics Technology Co., Ltd. by up to 11,932,036 shares, which is no more than 3% of the total share capital [1][2][3] - As of the announcement date, Guoshou Chengda holds 30,957,960 shares, representing 7.78% of the company's total share capital, all of which were acquired prior to the company's IPO [1][2] - The reduction will occur through block trading and centralized bidding, with a maximum of 3,977,345 shares to be sold via centralized bidding and 7,954,691 shares through block trading [2][3] Group 2 - The reduction period is set from September 24, 2025, to December 23, 2025, and any changes in the company's stock structure during this period will adjust the number of shares accordingly [2] - The reason for the reduction is stated as personal funding needs of the shareholder [2][3] - Guoshou Chengda has committed to not exceeding the legal limits on share reductions and will disclose any plans for share sales in advance [4][5]